Literature DB >> 11694344

Polycystic ovary syndrome: the new millenium.

R S Legro1.   

Abstract

Our understanding of Polycystic Ovary Syndrome (PCOS) has been hampered by varying diagnostic criteria, and ignorance of the etiology of the syndrome. PCOS women are uniquely insulin resistant and obesity aggravates this underlying predisposition to insulin resistance. Diagnostic criteria which focus on hyperandrogenism and/or menstrual irregularity are more likely to identify insulin resistant women, than such criteria as abnormal gonadotropin secretion or ovarian morphology. The lack of a clear etiologic mechanism to the syndrome has led to a multitude of symptom-oriented treatments with few therapies improving all aspects of the endocrine syndrome of PCOS. Improving insulin sensitivity has become established as a baseline treatment strategy in PCOS. There are, however, few randomized controlled trials of adequate power to provide an evidence based guide to treatment in PCOS.

Entities:  

Mesh:

Year:  2001        PMID: 11694344     DOI: 10.1016/s0303-7207(01)00640-2

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

1.  Women with epilepsy: can the treatment be worse than the disease?

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

Review 2.  Best practice in primary care pathology: review 4.

Authors:  W S A Smellie; J Forth; S Sundar; E Kalu; C A M McNulty; E Sherriff; I D Watson; C Croucher; T M Reynolds; P J Carey
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

3.  Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors:  E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia.

Authors:  Anindita Nandi; Xiangyuan Wang; Domenico Accili; Debra J Wolgemuth
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

Review 5.  Genetic and environmental aspect of polycystic ovary syndrome.

Authors:  E Carmina
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

6.  Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism?

Authors:  F Orio; S Palomba; T Cascella; L Tauchmanovà; S Di Biase; D Labella; T Russo; M Pellicano; S Savastano; F Zullo; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

7.  The blood-follicle barrier (BFB) in disease and in ovarian function.

Authors:  Michelle K Y Siu; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

8.  PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women.

Authors:  Chen Chen; Jessica Wickenheisser; Kathryn G Ewens; Wendy Ankener; Richard S Legro; Andrea Dunaif; Jan M McAllister; Richard S Spielman; Jerome F Strauss
Journal:  Mol Hum Reprod       Date:  2009-05-29       Impact factor: 4.025

Review 9.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

10.  RUNX2, GPX3 and PTX3 gene expression profiling in cumulus cells are reflective oocyte/embryo competence and potentially reliable predictors of embryo developmental competence in PCOS patients.

Authors:  Xin Huang; Cuifang Hao; Xiaofang Shen; Yuhua Zhang; Xiaoyan Liu
Journal:  Reprod Biol Endocrinol       Date:  2013-11-26       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.